New and emerging targeted treatments in advanced non-small-cell lung cancer

Fred R. Hirsch, Kenichi Suda, Jacinta Wiens, Paul A. Bunn

Research output: Contribution to journalReview articlepeer-review

347 Scopus citations


Targeted therapies are substantially changing the management of lung cancers. These treatments include drugs that target driver mutations, those that target presumed important molecules in cancer cell proliferation and survival, and those that inhibit immune checkpoint molecules. This area of research progresses day by day, with novel target discoveries, novel drug development, and use of novel combination treatments. Researchers and clinicians have also extensively investigated the predictive biomarkers and the molecular mechanisms underlying inherent or acquired resistance to these targeted therapies. We review recent progress in the development of targeted treatments for patients with advanced non-small-cell lung cancer, especially focusing on data from published clinical trials.

Original languageEnglish
Pages (from-to)1012-1024
Number of pages13
JournalThe Lancet
Issue number10048
StatePublished - 3 Sep 2016
Externally publishedYes


Dive into the research topics of 'New and emerging targeted treatments in advanced non-small-cell lung cancer'. Together they form a unique fingerprint.

Cite this